Search

Your search keyword '"Ogasawara, Sadahisa"' showing total 624 results

Search Constraints

Start Over You searched for: Author "Ogasawara, Sadahisa" Remove constraint Author: "Ogasawara, Sadahisa"
624 results on '"Ogasawara, Sadahisa"'

Search Results

1. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024

2. Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)

3. Risk factors of unintentional piecemeal resection in endoscopic mucosal resection for colorectal polyps ≥ 10 mm

4. Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma

5. Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis

7. Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in patients with advanced hepatocellular carcinoma with macrovascular invasion: DEPARTURE trial.

11. Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury

12. Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000

13. Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients

15. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

16. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

17. A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis

18. Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis

19. Diagnostic value of peroral cholangioscopy in addition to computed tomography for indeterminate biliary strictures

23. “Salvage techniques” are the key to overcome difficult biliary cannulation in endoscopic retrograde cholangiopancreatography

24. The efficacy of contrast-enhanced computed tomography on the management of gastroesophageal varices in patients with hepatocellular carcinoma

25. The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort

26. SAT-335 Pathological dynamics and clinical implications of hepatitis in cancer patients undergoing immune checkpoint inhibitor

27. Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy

28. Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.

29. Analysis of tumor biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) from a phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, in combination with lenvatinib.

30. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan

31. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

32. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma

33. T1 Mapping Enabled Detection and Follow-up of Rare Immune Checkpoint Inhibitor Myocarditis

35. A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study

36. Situation of hepatitis virus tests and measures to link test-positive individuals to specialists: a survey of institutions in Chiba, Japan, specializing in liver diseases

37. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial

39. Practicality of STAT3 Gene Polymorphisms and Sorafenib Trough Concentration as Biomarkers for Sorafenib-Induced Hand-Foot Skin Reaction in Hepatocellular Carcinoma

40. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD

41. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD.

43. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment

46. Supplementary Figure from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

47. Supplementary Table from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

48. Supplementary Data from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

49. Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy

50. Risk Factors of Unintentional Piecemeal Resection in Endoscopic Mucosal Resection for Colorectal Polyps ≥ 10 mm

Catalog

Books, media, physical & digital resources